Fred Hutchinson Cancer Research Center

The standard thing to do when a child is treated for brain cancer is to put some of the tumor cells under a microscope, and see what kind of cancer it is.

But new research led by Dr. Jim Olson of the Fred Hutchinson Cancer Research Center and Seattle Children’s compared that type of diagnosis with results of genetic testing of the same tumors and found that 71 percent were actually another type altogether.

Vice President Joe Biden used his visit to Seattle Monday to call for breaking down barriers that keep scientists from cooperating to fight cancer.

Imagine getting a box containing a ball of bones and fur regurgitated from an owl. That’s just one of the gross things a Seattle researcher plans to send to girls nationwide, as part of a new bid to attract girls into science.

Kina McAllister works as a research technician at the Fred Hutchinson Cancer Research Center, and she’s the mind behind Stem Box. The subscription service sends out a kit each month geared toward awakening the scientist in young girls.

Seattle-based scientists are reporting more encouraging results from treating blood cancer patients with souped-up immune cells.

The trial, part of a larger study by Seattle-based biotechnology Juno Therapeutics, involved about 50 people with three different types of blood cancer. Patients in this type of trial typically have not responded to the usual treatments, and are nearly out of options.

Scientists from Fred Hutchinson Cancer Research Center re-engineered the patients’ immune cells and injected them back into their bodies. Dr. Cameron Turtle of Fred Hutch reported Monday that 91 percent of those with acute lymphoblastic leukemia went into remission.

A Seattle company hopes its device will accelerate the development of cancer drugs by letting scientists test multiple drugs simultaneously within a person’s living tumor.

The device, called a CIVO, uses eight micro-needles to inject a tumor with microdoses of multiple cancer drugs. Doctors then would be able test the effects of eight different drugs at once, saving research time.

“What CIVO enables you to do is to have essentially multiple shots on goal,” said Rich Klinghoffer, Chief Scientific Officer of Presage Biosciences which developed the CIVO from research at the Seattle’s Fred Hutchinson Cancer Research Center.

Fifty years ago this weekend, the U.S. surgeon general released a landmark report blaming smoking for a number of health risks.

A new study co-authored by Seattle researchers says the campaign against smoking has saved about eight million lives since. That’s more than the population of Washington state, or put another way, it’s like preventing about five full Metro buses from driving off a cliff every day for 50 years.

Editor's Note: This is the second installment of a two-part series. Learn how scorpion vemon led local researchers to the brink of discovery of a new class of drugs in Part 1.

Consider the chemical elegance of a potato. Or a petunia. Or a horseshoe crab.

Somewhere in each of those organisms is a special little protein uniquely equipped to do what medicines do: barge in on biological processes and mess with them. With a little tweaking, it’s possible they could be trained to, say, keep cancer cells from spreading.

A few years ago, Dr. Jim Olson and his team at the Fred Hutchinson Cancer Research Center had figured out how to make those proteins by the thousands, but they hadn’t yet figured out how to pay for it.

The Deathstalker scorpion is about the size of your palm. It’s yellow and surly, its venom a seething cocktail of neurotoxins.

And somewhere in that poison soup is a very special little molecule, called chlorotoxin, designed to penetrate a prey animal’s brain. That effect happens to come in very handy: while it’s in there, it sticks to cancer cells while slipping right by healthy ones.

Jim Olson, a pediatric oncologist at Seattle Children’s Hospital and a researcher at the Fred Hutchinson Cancer Research Center, put that toxin to work.